Allergan Generics
Teva to buy Allergan generic drug unit for $40.5 bn
Israeli pharmaceutical giant Teva said on July 27 that it was buying the generic drug business of Allergan for $40.5 billion, consolidating its position as a world leader in generics.
Teva will pay $33.75 billion in cash and offer $6.75 billion of its stock to Allergan, the company said, in a major move that will further shake up the industry.